Business Description
Context Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US21077P1084
Description
Context Therapeutics Inc is a clinical-stage biopharmaceutical company advancing medicines for solid tumors. The development team is advancing a pipeline of innovative therapies with a primary focus on treating female, hormone-dependent cancer, including breast, ovarian, and endometrial cancer. The company's preclinical program, CTIM-76, is an anti-Claudin 6 ("CLDN6") x anti-CD3 bispecific antibody ("bsAb") that is intended to redirect T-cell-mediated lysis toward malignant cells expressing CLDN6.
Financial Strength
8/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | 347.55 | |||||
| Equity-to-Asset | 0.97 | |||||
| Debt-to-EBITDA | -0.01 | |||||
| Interest Coverage | N/A |
N/A
|
N/A
| |||
| Piotroski F-Score | 2/9 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year EPS without NRI Growth Rate | -16.1 | |||||
| 3-Year FCF Growth Rate | -135.4 | |||||
| Future 3-5Y EPS without NRI Growth Rate Estimate | 35.11 |
Momentum Rank
9/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 5-Day RSI | 21.93 | |||||
| 9-Day RSI | 27.06 | |||||
| 14-Day RSI | 30.42 | |||||
| 3-1 Month Momentum % | -5.74 | |||||
| 12-1 Month Momentum % | 140.24 |
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 36.91 | |||||
| Quick Ratio | 36.91 | |||||
| Cash Ratio | 36.36 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -16.1 | |||||
| Shareholder Yield % | -0.2 |
Profitability Rank
2/10
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| ROE % | -67.41 | |||||
| ROA % | -63.04 | |||||
| ROIC % | -5104.61 | |||||
| 3-Year ROIIC % | 418.7 | |||||
| ROC (Joel Greenblatt) % | -51498.42 | |||||
| ROCE % | -72.71 | |||||
| Years of Profitability over Past 10-Year | 1 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PB Ratio | 1.29 | |||||
| Price-to-Tangible-Book | 1.24 | |||||
| EV-to-EBIT | -0.72 | |||||
| EV-to-Forward-EBIT | -0.92 | |||||
| EV-to-EBITDA | -0.72 | |||||
| EV-to-Forward-EBITDA | -1.35 | |||||
| EV-to-FCF | -1.39 | |||||
| Price-to-Net-Current-Asset-Value | 1.25 | |||||
| Price-to-Net-Cash | 1.26 | |||||
| Earnings Yield (Greenblatt) % | -138.89 | |||||
| FCF Yield % | -15.63 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with NAS:CNTX
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Context Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil $) | |||
| EPS (TTM) ($) | -0.91 | ||
| Beta | 2.04 | ||
| 3-Year Sharpe Ratio | 0.1 | ||
| 3-Year Sortino Ratio | 0.16 | ||
| Volatility % | 74.75 | ||
| 14-Day RSI | 30.42 | ||
| 14-Day ATR ($) | 0.124642 | ||
| 20-Day SMA ($) | 1.5305 | ||
| 12-1 Month Momentum % | 140.24 | ||
| 52-Week Range ($) | 0.8463 - 2.75 | ||
| Shares Outstanding (Mil) | 75 |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 2 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Context Therapeutics Inc Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Context Therapeutics Inc Stock Events
| Event | Date | Price ($) | ||
|---|---|---|---|---|
| No Event Data | ||||
Context Therapeutics Inc Frequently Asked Questions
What is Context Therapeutics Inc(CNTX)'s stock price today?
The current price of CNTX is $1.39. The 52 week high of CNTX is $2.75 and 52 week low is $0.85.
When is next earnings date of Context Therapeutics Inc(CNTX)?
The next earnings date of Context Therapeutics Inc(CNTX) is 2025-02-28 Est..
Does Context Therapeutics Inc(CNTX) pay dividends? If so, how much?
Context Therapeutics Inc(CNTX) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers